Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12357206 | 0.97 | LPL (0.36) | LPLLIPGALOX5APFEN1CA1 | |
| SCHEMBL2486780 | 0.93 | LPL (0.35) | LPLLIPGALOX5APFEN1CA1 | |
| SCHEMBL12760441 | 0.93 | LPL (0.37) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12357207 | 0.91 | LPL (0.39) | LPLLIPGALOX5APFEN1CA1 | |
| SCHEMBL13218909 | 0.87 | LPL (0.36) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL9913718 | 0.86 | ALOX5AP (0.30) | ALOX5APFEN1 | |
| SCHEMBL2393633 | 0.80 | LPL (0.36) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL18099489 | 0.80 | ERN1 (0.42) | ALOX5APFEN1GRM2 | |
| SCHEMBL10021838 | 0.80 | ALOX5AP (0.38) | ALOX5APFEN1GRM2 | |
| SCHEMBL12357204 | 0.78 | GPR3 (0.40) | ALOX5APFEN1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8197709-B2 | Liquid-crystalline compounds | MERCK PATENT GESELLSCHAFT MIT BERSCHRANKTER HAFTUNG (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-2319897-A1 | Liquid crystal compounds | Merck Patent GmbH (DE) | 2011-05-11 | — | — | EP | disclosed |
| US-20110101271-A1 | LIQUID-CRYSTALLINE COMPOUNDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110101271-A1 | LIQUID-CRYSTALLINE COMPOUNDS | GJB2, GIGYF2, AQP3 | LPL 4423/4885LIPG 4705/4885ALOX5AP 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.